The short-term effects of combined modified constraint-induced movement therapy and botulinum toxin injection for children with spastic hemiplegic cerebral palsy

Neuropediatrics. 2009 Dec;40(6):269-74. doi: 10.1055/s-0030-1252049. Epub 2010 May 5.

Abstract

Objective: The aim of this study was to investigate whether modified constraint-induced movement therapy (mCIMT) following a botulinum type A toxin (BoNT-A) injection enhances the effects of the BoNT-A injection into the spastic upper limb of children with hemiplegic cerebral palsy (CP).

Methods: A combined therapy with mCIMT and BoNT-A was given to 17 children in group A. Fifteen children in group B received only the BoNT-A injection. The muscle tone, the movement pattern, and the How Often and the How Well scales in the revised Pediatric Motor Activity Log (revised PMAL) were assessed before and 3 weeks after intervention.

Results: Three participants in group A dropped out due to poor tolerance of mCIMT. There were significant improvements in the muscle tone and the movement patterns for both groups (p<0.05), and the changes were not significantly different between the two groups. The How Often and the How Well scales in the revised PMAL were significantly improved in group A (p<0.05), but not in group B.

Conclusion: A combined therapy of mCIMT and BoNT-A seems to be helpful to enhance the effects of the BoNT-A injection in the functional use of the affected limb in children with hemiplegic CP.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins, Type A / therapeutic use*
  • Cerebral Palsy / complications
  • Cerebral Palsy / drug therapy*
  • Cerebral Palsy / rehabilitation*
  • Child
  • Child, Preschool
  • Disability Evaluation
  • Exercise Therapy / methods*
  • Female
  • Humans
  • Infant
  • Male
  • Motor Activity / physiology
  • Neurologic Examination
  • Neuromuscular Agents / therapeutic use*
  • Physical Therapy Modalities
  • Restraint, Physical / methods*
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A